Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. [electronic resource]
Producer: 20140904Description: 795-802 p. digitalISSN:- 1096-8652
- Antimetabolites, Antineoplastic -- therapeutic use
- Azacitidine -- therapeutic use
- Drug Therapy, Combination
- Gene Expression
- Humans
- Immunologic Factors -- therapeutic use
- Interferon-gamma -- biosynthesis
- Interleukin-2 -- biosynthesis
- Lenalidomide
- Leukemia, Myeloid, Acute -- drug therapy
- Receptors, Tumor Necrosis Factor, Type II -- antagonists & inhibitors
- Recurrence
- Remission Induction
- T-Lymphocytes, Cytotoxic -- drug effects
- T-Lymphocytes, Regulatory -- drug effects
- Thalidomide -- analogs & derivatives
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.